Norovirus, often erroneously called the stomach flu, sickens an estimated 21 million Americans and 685 million people worldwide every year, and though there's no preventive vaccine, a promising contender is in the works.
The virus causes several nightmarish days of severe vomiting and diarrhea, often accompanied by fever, body aches and dehydration. It's "more a nauseating nuisance than a public health crisis," said The Atlantic, but scientists have nevertheless been at work on a norovirus vaccine for years. In September of last year, the first volunteers were dosed in Moderna's advanced clinical trial for a norovirus vaccine that showed encouraging results in preliminary trials.
What did the commentators say? Experts have expressed caution about how feasible it will be to deliver a norovirus vaccine. "Will it work here? Keep a bucket handy, just in case," said the American Council on Science and Health in a post on X about the Moderna trial. That's because norovirus has been "devilishly difficult to even contemplate vaccinating against" given how rapidly it mutates, said the BBC. Some skepticism also stems from the July 2024 failure of a HilleVax vaccine for norovirus in infants.
A recent winter surge of norovirus cases in the northern hemisphere, however, has renewed calls for vaccine development. "What better way to remind people of the power of vaccines than to eliminate the misery of puking?" said Alexandra Sifferlin at The New York Times. And while the norovirus "jab won't eliminate the bug, it could significantly reduce its impact on the health system," said The Independent.
What next? Moderna researchers claim that "earlier trials of the vaccine have shown it generates a strong immune response in humans" and will "explore whether the jab is effective against the virus itself and, if so, how long protection lasts," said The Guardian. Moderna's norovirus inoculation uses the same mRNA technology that produced the company's revolutionary Covid-19 vaccines in 2020.
Moderna needs to complete a final phase III trial before submitting for regulatory approval. The company hopes to enroll 25,000 global trial volunteers over two years. That means that even if the vaccine is shown to be safe and effective, it will not be available to the public until late 2026 or 2027. In the meantime, experts recommend washing your hands frequently. |